Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 long-term safety and tolerability study of ampreloxetine in symptomatic neurogenic orthostatic hypotension
MOH_2020-04-21_008704Phase 3Not yet recruiting
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ampreloxetine in Neurogenic Orthostatic Hypotension (nOH), sponsored by Theravance Biopharma, Inc. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
ampreloxetine
03
Conditions
Neurogenic Orthostatic Hypotension (nOH)
Beyond the preview
Go deeper on MOH_2020-04-21_008704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-04-21_008704.